C8 Antibody (Polyclonal)

A goat antiserum raised against human C8 protein.


Product Specifications

Citations 5
Clonality

Polyclonal

Immnogen
Applications See citations and technical data sheet for application info.
Concentration > 40 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human, Baboon, Dog, Rabbit, Guinea Pig, Cat, Hamster, Horse, Rat, Mouse

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A309
Catalog Number (CE) N/A
Size 2.0 mL
Price (USD) $230.00
Price (EURO) 200,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A goat antiserum raised against human C8 protein.

Size 2.0 mL
Concentration

> 40 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide
Clonality Polyclonal
Immunogen Highly purified human C8 protein
Conjugate Unconjugated
Cross Reactivity Human, Baboon, Dog, Rabbit, Guinea Pig, Cat, Hamster, Horse, Rat, Mouse
Isotype Goat IgG
Purity N/A
Source

Goat

Specificity The anti-human C8 polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodiffusion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C8 at varying concentrations.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

C8 is a glycoprotein which is present in normal human serum/plasma at approximately 50 µg/mL. C8 is unique in that it is made up of 3 non-identical subunits, α, β, and γ. The molecular weights of these subunits are 64 kD, 64 kD, and 22 kD, respectively. The α and γ chains are linked together by a disulfide bond, whereas the β chain is associated to the α-γ complex by a non-covalent bond. The main function of the C8 protein is to initiate the binding of C9 to form the Membrane Attack Complex (MAC). With activation of the classical or alternative pathways of the complement system, C5 convertase cleaves the C5 chain into C5a and C5b. C5b remains bound to the convertase and will combine with C6 to form a C5b,6 complex. This complex normally interacts with C7 to form C5b,6,7 that becomes partially embedded in the target cell outer membrane. The C5b,6,7 complex will subsequently bind C8 and multiple C9 molecules completing the terminal pathway. The C5b,6,7,8,9, or C5b-9 complex, is also known as the Membrane Attack Complex (MAC), which causes irreversible damage to the target cell membrane.

Citations

Title Year Applications Sample Species Sample Sample Details

CspA from Borrelia burgdorferi inhibits the terminal complement pathway.

2013

IF

Bacteria

Borrelia burgdorferi

Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid.

2015

ELISA, WB

Human

Serum

Acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS)

Abundant lipid and protein components of drusen.

2010

IF

Human

Eye Tissue

Drusen

Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis.

2016

WB

Human

Serum

C8 Deficient w/Invasive meningococcal disease

Complement membrane attack complex formation and infectivity of Trichinella spiralis and T. nativa in rats.

2009

IF, IHC

Mouse

Muscle

Trichinella spiralis